H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 32.85 DKK -0.3%
Market Cap: 32.7B DKK
Have any thoughts about
H Lundbeck A/S?
Write Note

Gross Margin
H Lundbeck A/S

79.9%
Current
79%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
79.9%
=
Gross Profit
17.1B
/
Revenue
21.4B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
DK
H Lundbeck A/S
CSE:HLUN A
32.7B DKK
80%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK
85%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
69%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
77%
CH
Roche Holding AG
SIX:ROG
197.2B CHF
73%
UK
AstraZeneca PLC
LSE:AZN
159B GBP
82%
CH
Novartis AG
SIX:NOVN
169.7B CHF
75%
US
Pfizer Inc
NYSE:PFE
149.4B USD
71%
Country DK
Market Cap 32.7B DKK
Gross Margin
80%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 729.3B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.6T DKK
Gross Margin
85%
Country US
Market Cap 347.8B USD
Gross Margin
69%
Country US
Market Cap 248.3B USD
Gross Margin
77%
Country CH
Market Cap 197.2B CHF
Gross Margin
73%
Country UK
Market Cap 159B GBP
Gross Margin
82%
Country CH
Market Cap 169.7B CHF
Gross Margin
75%
Country US
Market Cap 149.4B USD
Gross Margin
71%
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
32.6B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
65.73 DKK
Undervaluation 50%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
79.9%
=
Gross Profit
17.1B
/
Revenue
21.4B
What is the Gross Margin of H Lundbeck A/S?

Based on H Lundbeck A/S's most recent financial statements, the company has Gross Margin of 79.9%.